Instituto Rosenbusch (BUE:ROSE) Margin of Safety % (DCF Earnings Based): N/A (As of Jun. 26, 2026)


BUE:ROSE Instituto Rosenbusch SA BUE:ROSE
39 GF Score
Price ARS160.50
GF Value ARS61.70
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Instituto Rosenbusch Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Instituto Rosenbusch's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

BUE:ROSE vs ZTS, UTHR, VTRS: Margin of Safety % (DCF Earnings Based) Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Instituto Rosenbusch's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Instituto Rosenbusch Margin of Safety % (DCF Earnings Based) vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Instituto Rosenbusch's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where Instituto Rosenbusch's Margin of Safety % (DCF Earnings Based) falls into.


BUE:ROSE
39GF Score
Instituto Rosenbusch SA BUE:ROSE
Margin of Safety % (DCF Earnings Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Instituto Rosenbusch (BUE:ROSE) Overvalued in 2026?

Based on GuruFocus' analysis, Instituto Rosenbusch stock appears to be overvalued. The current stock price of ARS160.50 is trading 160.1% above its estimated GF Value™ of ARS61.70. GuruFocus considers Instituto Rosenbusch to be Significantly Overvalued.

Key valuation signals for BUE:ROSE:

  • Margin of Safety % (DCF Earnings Based): N/A
  • GF Value™: ARS61.70 vs. price of ARS160.50 (160.1% above fair value)
  • GF Score™: 39/100 with 4 warning signs

No single metric tells the full story. See the BUE:ROSE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Instituto Rosenbusch Business Description

Address Hipolito Yrigoyen 1628, Buenos Aires, ARG, C1089AAF
Instituto Rosenbusch SA is a pharmaceutical company based in Argentina. The company is engaged in the processing and industrialization of biological, chemical, pharmaceutical products of any kind, nature or destination, preferably for veterinary use or intended to combat pests and diseases of the agricultural exploitation. The company has line of products such as Biologicals and pharmaceuticals. Biologicals offer Campy 3, Cultivac 6M and Bovine Antibrucelosis. Pharmaceuticals offer Diclosan A Intrammamary, Diclosan S Intrammamary and Mastilina V-S.
39GF Score

Get the complete analysis for BUE:ROSE

Margin of Safety % (DCF Earnings Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

ARS160.50
Price
ARS61.70
GF Value